TRIlogy-5
Multiple myeloma
A Phase 3, randomized, open-label study comparing ramantamig (JNJ-79635322) and teclistamab in patients with relapsed or refractory MM who have received 1–3 prior lines of therapy
Phase
Compound
Ramantamig (JNJ-79635322; BCMA × GPRC5D × CD3 trispecific Ab) or teclistamab (BCMA × CD3 bispecific Ab)
NCT identifier
NCT07518186
Enrollment
N=~700
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- Relapsed or refractory MM
- 1–3 prior lines of therapy, including anti-CD38 Ab and lenalidomide
- ECOG PS of 0–2
- No known active or prior CNS involvement or clinical signs of meningeal involvement of MM
Study
design
Primary outcomes:
- ≥CR
- PFS
Secondary outcomes†:
- ORR
- ≥VGPR
- DOR
- MRD-negative CR
- MRD-negative CR at 1 year and at 5 years
- OS
- TTNT
- Safety
- HRQoL
*Not a complete list of inclusion and exclusion criteria. †Not a complete list of outcomes.
Ab, antibody; BCMA, B-cell maturation antigen; CD, cluster of differentiation; CNS, central nervous system; CR, complete response; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; GPRC5D, G protein–coupled receptor class C group 5 member D; HRQoL, health-related quality of life; MM, multiple myeloma; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; R, randomized; SC, subcutaneous; TTNT, time to next line of therapy; VGPR, very good partial response.